BioPharma Credit Ord (LSE:BPCR) - Investment trust price - Overview


Investment Trust Report

BioPharma Credit PLC BPCR

Last Price
$1.05

Day Change
0.01|0.72%

As of 18/04/2019
18:29:29 BST | USD
Minimum 15 Minutes Delay.

Last Close1.04
Day Range1.04 - 1.05
52-Wk Range1.02 - 1.12
Mkt Cap Mil1,442.63
Yield %6.67
Estimated Nav1.01
Premium %3.52
12M Avg Prem %4.35
Last Actual NAV1.03
Last NAV Date28/02/2019

Share Price Performance (USD)

Key Statistics (USD)
Total Assets1,393.579m
Net Assets1,393.579m
Market Capitalisation1,442.629m
Gross Gearing100%
Net Gearing46%
Average Daily Shares Traded (1 Yr)0.290m
Average Daily Value Traded (1 Yr)0.305m
Ongoing Charge (2018)1.56%
DomicileUnited Kingdom
Legal StructureClosed End Fund
Traded CurrencyUSD
ISINGB00BDGKMY29
Launch Date27 Mar 2017
Financial Year EndDec 2019
Next AGMJun 2019
NAV FrequencyMonthly
Dividend FrequencyNone
Valuation Statistics
 22/04/20191 Yr High1 Yr Low
Price1.051.121.03
NAV*1.011.060.98
Discount/Premium3.529.45-1.20
Category Discount---
Z-Statistics (1Yr)-0.65  

Total Returns (USD) 22/04/2019

 Chg (%)  
More ...
Price-0.47 
NAV-3.42
Cat Price-1.34
Cat NAV-0.35
 
Latest Dividends
TypeDividendEx-Dividend DateFinancial Year
Income.017528/02/20192018
Income - Special.001828/02/20192018
Income.017501/11/20182018
Income.017530/08/20182018
Income.013431/05/20182018
Director Dealings
TradedActionNotifierPriceAmountValue
14/01/2019DMr. Harry Abraham Hyman83.213428.00
17/07/2018DMr. Harry Abraham Hyman81.272520.00

Morningstar Rating™

Not Rated

Morningstar® Category

USD Corporate Bond

Benchmarks

Morningstar® Benchmark

FTSE World TR GBP
Fund Structure
Share Type# of Shares
Ordinary Share1,373.932m

Investment Objective

The company will seek to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The company will seek to achieve its investment objective predominantly through direct or indirect exposure to Debt Assets. The Company may also invest in equity issued by a LifeSci Company, acquired directly from the LifeSci Company; or in the secondary market.
Managers
Pedro Gonzalez de Cosio27/03/2017
Pablo Legorreta27/03/2017
Martin Friedman27/03/2017

Directors

Colin Bond, Duncan Budge, Harry Hyman, Stephanie Leouzon, Jeremy Sillem
Fund prices are updated every weekday after the close of trading and before 11 p.m. wherever possible. All figures are as at Last Close, on a cum income basis with debt valued at fair and in traded currency unless otherwise stated (we do not fair value debt for split capital trusts). Performance returns are presented in U.S. Dollars (USD) and calculated on a capital only basis with debt valued at par.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.